Journal ArticleDOI
Comorbidity and functional status are independent in older cancer patients.
Reads0
Chats0
TLDR
Both the Charlson and CIRS-G scales are reliable tools for use in trials of older cancer patients and can be tested in further studies as predictors of outcomes such as toxicity of treatment, changes in functional status, or survival.Abstract:
PURPOSEComorbidity is a frequent and often therapeutically limiting problem in older cancer patients. However, to date, there is no standard measure of the comorbidity burden available for these patients. We tested the performance of two comorbidity scales and their relationship with functional status.PATIENTS AND METHODSThe Cumulative Illness Rating Scale-Geriatric (CIRS-G) was compared with the Charlson scale in 203 patients who received a comprehensive geriatric assessment (CGA) in our Senior Adult Oncology Program (SAOP). Study end points were variability, reliability, correlation with Eastern Cooperative Oncology Group (ECOG) performance status (PS), Activities of Daily Living (ADL), and Instrumental Activities of Daily Living (IADL). The relative weight of comorbidity versus tumor stage in the correlations with functional status was assessed.RESULTSMedian age was 75 years (range, 63 to 91). Sixty-four percent of patients scored 0 on the Charlson scale versus 6% on the CIRS-G. The correlation between...read more
Citations
More filters
Journal ArticleDOI
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
Michael Hallek,Bruce D. Cheson,Daniel Catovsky,Federico Caligaris-Cappio,Guillaume Dighiero,Hartmut Döhner,Peter Hillmen,Michael J. Keating,Emili Montserrat,Kanti R. Rai,Thomas J. Kipps +10 more
TL;DR: The International Workshop on Chronic Lymphocytic Leukemia (IWCLL) to provide updated recommendations for the management of CLL in clinical trials and general practice is provided.
Journal ArticleDOI
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.
Mohamed L. Sorror,Michael B. Maris,Michael B. Maris,Rainer Storb,Rainer Storb,Frédéric Baron,Brenda M. Sandmaier,Brenda M. Sandmaier,David G. Maloney,David G. Maloney,Barry E. Storer,Barry E. Storer +11 more
TL;DR: The new simple index provided valid and reliable scoring of pretransplant comorbidities that predicted nonrelapse mortality and survival and will be useful for clinical trials and patient counseling before HCT.
Journal ArticleDOI
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
Michael Hallek,Kirsten Fischer,Günter Fingerle-Rowson,Anna-Maria Fink,Raymonde Busch,Jiří Mayer,Manfred Hensel,Georg Hopfinger,G D Hess,U. Von Grünhagen,Matthias Bergmann,John Catalano,Pier Luigi Zinzani,Federico Caligaris-Cappio,John F. Seymour,Alain Berrebi,Ulrich Jäger,Bruno Cazin,Marek Trneny,Anne Westermann,Clemens M. Wendtner,Barbara Eichhorst,Peter Staib,Andreas Bühler,Dirk Winkler,Thorsten Zenz,S Böttcher,Matthias Ritgen,Myriam Mendila,Michael Kneba,Hartmut Döhner,Stephan Stilgenbauer +31 more
TL;DR: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab improves progression-free survival and overall survival in patients with chronic lymphocytic leukaemia, and the results suggest that the choice of a specific first-line treatment changes the natural course of chronic lymphocytes.
Journal ArticleDOI
How to measure comorbidity: a critical review of available methods
TL;DR: The Charlson Index, the CIRS, the ICED and the Kaplan Index are valid and reliable methods to measure comorbidity that can be used in clinical research.
Journal ArticleDOI
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
Richard R. Furman,Jeff P. Sharman,Steven Coutre,Bruce D. Cheson,John M. Pagel,Peter Hillmen,Jacqueline C. Barrientos,Andrew D. Zelenetz,Thomas J. Kipps,Ian W. Flinn,Paolo Ghia,Herbert Eradat,Thomas J. Ervin,Nicole Lamanna,Bertrand Coiffier,Andrew R. Pettitt,Shuo Ma,Stephan Stilgenbauer,Paula Cramer,Maria Aiello,Dave Johnson,Langdon L. Miller,Daniel Li,Thomas Jahn,Roger Dansey,Michael Hallek,Susan O'Brien +26 more
TL;DR: The combination of idelalisib and rituximab, as compared with placebo and r ituximabs, significantly improved progression-free survival, response rate, and overall survival among patients with relapsed CLL who were less able to undergo chemotherapy.
References
More filters
Journal ArticleDOI
A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation☆
TL;DR: The method of classifying comorbidity provides a simple, readily applicable and valid method of estimating risk of death fromComorbid disease for use in longitudinal studies and further work in larger populations is still required to refine the approach.
Journal ArticleDOI
Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living
M. P. Lawton,Elmne M. Brody +1 more
TL;DR: Two scales first standardized on their own population are presented, one of which taps a level of functioning heretofore inadequately represented in attempts to assess everyday functional competence, and the other taps a schema of competence into which these behaviors fit.
Journal ArticleDOI
Studies of illness in the aged. the index of adl: a standardized measure of biological and psychosocial function.
TL;DR: The Index of ADL as discussed by the authors was developed to study results of treatment and prognosis in the elderly and chronically ill. Grades of the Index summarize over-all performance in bathing, dressing, going to toilet, transferring, continence, and feeding.
Journal ArticleDOI
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
TL;DR: It is concluded that the adapted comorbidity index will be useful in studies of disease outcome and resource use employing administrative databases.
Journal Article
A predictive model for aggressive non-Hodgkin's lymphoma
Margaret A. Shipp,D. P. Harrington,James R. Anderson,James Olen Armitage,Gianni Bonadonna,G. Brittinger,Fernando Cabanillas,George P. Canellos,Bertrand Coiffier,Joseph M. Connors,R. A. Cowan,D. Crowther,Steve Dahlberg,M. Engelhard,Richard I. Fisher,Christian Gisselbrecht,Sandra J. Horning,Eric Lepage,T. A. Lister,J. H. Meerwaldt,Emili Montserrat,Nis I. Nissen,M. M. Oken,Bruce A. Peterson,Carlo Tondini,W. A. Velasquez,B. Y. Yeap +26 more
TL;DR: The international index and the age-adjusted international index should be used in the design of future therapeutic trials in patients with aggressive non-Hodgkin's lymphoma and in the selection of appropriate therapeutic approaches for individual patients.
Related Papers (5)
Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living
M. P. Lawton,Elmne M. Brody +1 more